Evidence map›Paper›PMID 27821806›Full record

ArticleOncotarget2017

Investigation on tissue specific effects of pro-apoptotic micro RNAs revealed miR-147b as a potential biomarker in ovarian cancer prognosis.

Michael Kleemann, Jeremias Bereuther, Simon Fischer, Kim Marquart, Simon Hänle, Kristian Unger, Verena Jendrossek, Christian U Riedel, René Handrick, Kerstin Otte

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Balkan journal of medical genetics : BJMG · 2022
    Article
  5. Article
  6. Observational
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Michael KleemannInstitute of Applied Biotechnology, University of Applied Sciences Biberach, 88400 Biberach, Germany.
Jeremias BereutherInstitute of Applied Biotechnology, University of Applied Sciences Biberach, 88400 Biberach, Germany.
Simon FischerBoehringer Ingelheim Pharma GmbH and Co.KG, BP Process Development Germany, 88400 Biberach, Germany.
Kim MarquartInstitute of Applied Biotechnology, University of Applied Sciences Biberach, 88400 Biberach, Germany.
Simon HänleInstitute of Applied Biotechnology, University of Applied Sciences Biberach, 88400 Biberach, Germany.
Kristian UngerResearch Unit Radiation Cytogenetics, Helmholtz Zentrum München, 85764 Neuherberg, Germany.
Verena JendrossekInstitute of Cell Biology (Cancer Research), University of Duisburg-Essen, Medical School, 45122 Essen, Germany.
Christian U RiedelUniversity of Ulm, Faculty of Medicine, 89079 Ulm, Germany.
René HandrickInstitute of Applied Biotechnology, University of Applied Sciences Biberach, 88400 Biberach, Germany.
Kerstin OtteInstitute of Applied Biotechnology, University of Applied Sciences Biberach, 88400 Biberach, Germany.
University of Applied Sciences Biberach · DEUniversität Ulm · DEBoehringer Ingelheim (Germany) · DEHelmholtz Zentrum München · DEUniversity of Duisburg-Essen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development and progression of cancer can be ascribed to imbalances in gene regulation leading to aberrant cellular behavior. The loss of micro RNAs (miRNAs) exhibiting tumor-suppressive function has been demonstrated to be often causative for uncontrolled cell proliferation, migration or tissue infiltration. The installation of de novo tumor suppressive function by using pro-apoptotic miRNAs might be a promising therapeutic approach. In addition, there is a great demand for novel biomarkers for the prognosis of cancer, which prompted us to transfer a high content miRNA screening initially performed to identify bioprocess relevant miRNAs in Chinese hamster ovary (CHO) cells to human cancer cell lines . Analysis of screened miRNAs exhibiting strongest pro-apoptotic effects discovered globally and cross-species active candidates. The recovery rate of apoptosis inducing miRNAs was highest in the human ovarian carcinoma cell line SKOV3. Focusing on ovarian cell lines miR-1912, miR-147b and miR-3073a showed significant apoptosis induction in cell lines with different genetic background (SKOV3p53null, OVCAR3p53R248Q, TOV21G, TOV112Dp53R175H, A2780, A2780-cisp53K351N) alone and additive effects in combination with carboplatin. While expression analysis revealed a low endogenous expression of miR-1912 and miR-147b in SKOV3, miRNA expression was highly upregulated upon apoptosis induction using chemotherapeutics. Ectopic introduction of these miRNAs lead to enhanced activation of caspase-dependent death signaling and an induction of the pro-apoptotic proteins Bak1 and Bax and a reduced expression of Bcl2 and Bcl-xL. Finally, analysis of The Cancer Genome Atlas data revealed the expression of hsa-miR-147b-5p to show a positive influence on the median survival of ovarian cancer patients.

Indexed as

AdultAgedAged, 80 and overApoptosisBiomarkers, TumorBlotting, WesternCell Line, TumorFemaleHumansKaplan-Meier EstimateMicroRNAsMiddle AgedOvarian NeoplasmsPolymerase Chain ReactionPrognosisBiomarkers, TumorMicroRNAsMIRN147 microRNA, humanapoptosisbiomarkermiR-147bovarian cancerprognosis

Identifiers

PMID27821806
PMCPMC5386646
OpenAlexW2546422858

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.